India, July 3 -- India's pharmaceutical market is changing. Investors are no longer only looking at companies that sell basic medicines at scale. The bigger interest is now moving towards companies that can sell specialised medicines, work with global innovators, build strong doctor relationships and still grow profitably. This is where partnerships are becoming important because many global drug companies want strong local partners instead of building everything on their own.

Shark Tank India judge Namita Thapar's Emcure Pharma is one such company that is trying to use this strategy. The company has already crossed the USD 1 billion revenue milestone, with FY26 revenue growth of 16.6 percent, base business EBITDA margin expansion of ove...